Medical therapy for Crohn's disease: Top-down or step-up?

Digestive Diseases

Volumn 25, Issue 3, 2007, Pages 260-266

  Baert, Filip ^a   Caprilli, Renzo ^b,c   Angelucci, Erika ^b  

^a Division of Gastroenterology   (Belgium)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c POLICLINICO UMBERTO I   (Italy)

Author keywords

Crohn's disease treatment, pros and cons; Crohn's disease, medical therapy; Step up vs. top down strategy

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; METHOTREXATE; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

CLINICAL PRACTICE; CLINICAL RESEARCH; CONFERENCE PAPER; CROHN DISEASE; HIGH RISK PATIENT; HUMAN; IMMUNOMODULATION; MAINTENANCE THERAPY; MEDICAL LEAVE; PRIORITY JOURNAL; QUALITY OF LIFE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENMARK; METHODOLOGY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; RISK FACTOR; UNITED STATES;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; BIOLOGICAL MARKERS; CROHN DISEASE; DENMARK; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; REMISSION INDUCTION; RISK FACTORS; UNITED STATES;

EID: 35448971037     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000103897     Document Type: Conference Paper

References (21)

1. Hay AR, Hay JW: Inflammatory bowel disease: medical cost algorithms. J Clin Gastroenterol 1992;14:318-327.
2. Hommes D, Baert F, Van Assche G, et al: A randomized controlled trial evaluating the ideal medical management for Crohn's disease: top-down versus step-up strategies. Gastroenterology 2005;128(suppl 2):A577.
3. Daperno M, D'Haens G, Van Assche G, et al: Development and validation of a new, simplified endo scopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004;60:505-512.
4. Lichtenstein GR, Feagan BG, Cohen RD, et al: Serious infections and mortality in association with therapies for Crohn's disease: treat registry. Clin Gastroenterol Hepatol 2006;4:621-630.
5. Lichtenstein GR, Yan S, Bala M, et al: Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005;128:862-869.
6. Cosnes J, Nion-Larmurier I, Beaugerie L, et al: Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005;54:237-241.
7. Lemann M, Mary JY, Duclos B, et al (GETAID): Infliximab plus azathioprine for steroid dependent Crohn's disease patients: a randomised placebo-controlled trial. Gastroenterology 2006;130:1054-1061.
8. Markowitz J, Grancher K, Kohn N, et al: A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902.
9. Kugathasan S, Werlin SL, Martinez A, et al: Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000;95:3189-3194.
10. Jewell DP, Satsangi J, Lobo A, et al: Infliximab use in Crohn's disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol 2007;17:1047-1052.
11. Munkholm P, Langholz E, Davidsen M, et al: Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995;30:699-706.
12. Munkholm P, Langholz E, Davidsen M, et al: Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994;35:360-362.
13. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al: The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-260.
14. Silverstein MD, Loftus EV, Sandborn WJ, et al: Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999;117:49-57.
15. Papi C, Festa V, Fagnani C, et al: Evolution of clinical behaviour in Crohn's disease: predictive factors of penetrating complications. Dig Liver Dis 2005;37:247-253.
16. Abreu MT: Serologies in Crohn's disease: Can we change the gray zone to black and white? Gastroenterology 2006;131:664-666.
17. Sandborn WJ, Loftus EV: Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel diseases. Gut 2004;53:780-782.
18. Keane J, Gershon S, Wise RP, et al: Tuberculosis associated with infliximab, a tumor necrosis factor-α-neutralizing agent. N Engl J Med 2001;345:1098-1104.
19. Rampton DS: Preventing TB in patients with Crohn's disease needing infliximab or other anti-TNF therapy. Gut 2005,54:1360-1362.
20. Bongartz T, Sutton AJ, Sweeting MJ, et al: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-2285.
21. Valesini G, Montecucco C, Cutolo M: Recommendations for the use of biologic (TNF-α-blocking) agents in the treatment of rheumatoid arthritis in Italy. Clin Exp Rheumatol 2006;24:413-423.